Key result
Linagliptin increases postprandial filtration fraction by ~2% vs glimepiride, failing to reduce hyperfiltration.
Why the study?
To determine the effect of linagliptin on postprandial glomerular hyperfiltration compared with glimepiride in adults with type 2 diabetes.
Does linagliptin reduce postprandial glomerular hyperfiltration compared to glimepiride in overweight adults with type 2 diabetes without renal impairment?
RCT (n=23)
Double-blind
parallel-group
Does linagliptin reduce postprandial glomerular hyperfiltration compared to glimepiride in overweight adults with type 2 diabetes without renal impairment?
Mean Difference: 2.1
p-value: p=0.016
In overweight adults with type 2 diabetes, linagliptin does not reduce postprandial hyperfiltration compared to glimepiride, but rather increases filtration fraction and glomerular hydraulic pressure.
Does not reduce postprandial hyperfiltration versus glimepiride; challenges hypothesis and leaves open DPP-4 inhibitor effects on renal hemodynamics in T2D.
Aim To determine the effect of the dipeptidyl peptidase‐4 inhibitor linagliptin on postprandial glomerular hyperfiltration compared with the sulphonylurea glimepiride in adults with type 2 diabetes (T2D). Materials and Methods In this predefined substudy within a randomized, double‐blind, parallel‐group, intervention trial, overweight people with T2D without renal impairment were treated with once‐daily linagliptin 5 mg (N = 10) or glimepiride 1 mg (N = 13) as an add‐on to metformin for 8 weeks. After a standardized liquid protein‐rich meal, the glomerular filtration rate (GFR) and effective renal plasma flow were determined by inulin and para‐aminohippuric acid clearance, respectively, based on timed urine sampling. Intrarenal haemodynamics were estimated using the Gomez equations. Glucoregulatory/vasoactive hormones, urinary pH and fractional excretions (FE) of sodium, potassium and urea were measured. Results Compared with glimepiride, linagliptin increased the postprandial filtration fraction (FF; mean difference 2.1%‐point; P = .016) and estimated glomerular hydraulic pressure (mean difference 3.0 mmHg; P = .050), and tended to increase GFR ( P = .08) and estimated efferent renal arteriolar resistance (R E ; P = .08) from baseline to week 8. No differences in FE were noted. Glimepiride reduced HbA1c more than linagliptin (mean difference −0.40%; P = .004), without between‐group differences in time‐averaged postprandial glucose levels. In the linagliptin group, change in FF correlated with change in mean arterial pressure (R = 0.807; P = .009) and time‐averaged mean glucagon (R = 0.782; P = .008), but not with changes in glucose, insulin, intact glucagon‐like peptide‐1, renin or FE Na . Change in glucagon was associated with change in R E (R = 0.830; P = .003). Conclusions In contrast to our hypothesis, compared with glimepiride, linagliptin does not reduce postprandial hyperfiltration, yet appears to increase FF after meal ingestion by increasing blood pressure or R E .
No takes yet. Share an insight, caveat, or question.
Muskiet et al. (2021) conducted an RCT in type 2 diabetes (n=23). linagliptin vs. glimepiride 1 mg once-daily was evaluated on postprandial filtration fraction (FF) (MD 2.1%-point, p=0.016). Compared with glimepiride, linagliptin increased the postprandial filtration fraction (mean difference 2.1%-point; P=0.016) and did not reduce postprandial hyperfiltration.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: